RemeGen Co., Ltd. 9995.HK Stock
RemeGen Co., Ltd. Price Chart
RemeGen Co., Ltd. 9995.HK Financial and Trading Overview
RemeGen Co., Ltd. stock price | 29.6 HKD |
Previous Close | 34.35 HKD |
Open | 34.95 HKD |
Bid | 36.75 HKD x N/A |
Ask | 36.8 HKD x N/A |
Day's Range | 34.2 - 37.9 HKD |
52 Week Range | 29.7 - 74.8 HKD |
Volume | 4.83M HKD |
Avg. Volume | 2.14M HKD |
Market Cap | 34.79B HKD |
Beta (5Y Monthly) | 0.566458 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.03 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 67.34 HKD |
9995.HK Valuation Measures
Enterprise Value | 17.2B HKD |
Trailing P/E | N/A |
Forward P/E | -40 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 44.26875 |
Price/Book (mrq) | 4.242564 |
Enterprise Value/Revenue | 21.886 |
Enterprise Value/EBITDA | -15.15 |
Trading Information
RemeGen Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.566458 |
52-Week Change | 0.88% |
S&P500 52-Week Change | 20.43% |
52 Week High | 74.8 HKD |
52 Week Low | 29.7 HKD |
50-Day Moving Average | 40.45 HKD |
200-Day Moving Average | 48.24 HKD |
9995.HK Share Statistics
Avg. Volume (3 month) | 2.14M HKD |
Avg. Daily Volume (10-Days) | 1.95M HKD |
Shares Outstanding | 189.58M |
Float | 337.38M |
Short Ratio | N/A |
% Held by Insiders | 24.08% |
% Held by Institutions | 29.18% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -131.79% |
Operating Margin (ttm) | -161.67% |
Gross Margin | 74.86% |
EBITDA Margin | -144.46% |
Management Effectiveness
Return on Assets (ttm) | -13.20% |
Return on Equity (ttm) | -20.016% |
Income Statement
Revenue (ttm) | 785.88M HKD |
Revenue Per Share (ttm) | 1.45 HKD |
Quarterly Revenue Growth (yoy) | 12.09% |
Gross Profit (ttm) | 794.11M HKD |
EBITDA | -1135341824 HKD |
Net Income Avi to Common (ttm) | -1035774144 HKD |
Diluted EPS (ttm) | -2.24 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.62B HKD |
Total Cash Per Share (mrq) | 3.01 HKD |
Total Debt (mrq) | 152.24M HKD |
Total Debt/Equity (mrq) | 3.25 HKD |
Current Ratio (mrq) | 3.25 |
Book Value Per Share (mrq) | 8.674 |
Cash Flow Statement
Operating Cash Flow (ttm) | -1263056384 HKD |
Levered Free Cash Flow (ttm) | -1684570496 HKD |
Profile of RemeGen Co., Ltd.
Country | Hong Kong |
State | N/A |
City | Yantai |
Address | 58 Middle Beijing Road |
ZIP | N/A |
Phone | 86 53 56357 3672 |
Website | https://www.remegen.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 3332 |
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC218 and RC228 to treat ophthalmopathy. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
Q&A For RemeGen Co., Ltd. Stock
What is a current 9995.HK stock price?
RemeGen Co., Ltd. 9995.HK stock price today per share is 29.6 HKD.
How to purchase RemeGen Co., Ltd. stock?
You can buy 9995.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for RemeGen Co., Ltd.?
The stock symbol or ticker of RemeGen Co., Ltd. is 9995.HK.
Which industry does the RemeGen Co., Ltd. company belong to?
The RemeGen Co., Ltd. industry is Biotechnology.
How many shares does RemeGen Co., Ltd. have in circulation?
The max supply of RemeGen Co., Ltd. shares is 844.85M.
What is RemeGen Co., Ltd. Price to Earnings Ratio (PE Ratio)?
RemeGen Co., Ltd. PE Ratio is now.
What was RemeGen Co., Ltd. earnings per share over the trailing 12 months (TTM)?
RemeGen Co., Ltd. EPS is -3.03 HKD over the trailing 12 months.
Which sector does the RemeGen Co., Ltd. company belong to?
The RemeGen Co., Ltd. sector is Healthcare.
RemeGen Co., Ltd. 9995.HK included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
Nasdaq EM Plus Korea Small Cap NQEMKRSCGBP | 1476.35 GBP 1888.16 USD |
<0.01
|
— — | 1476.35 GBP 1888.16 USD | 1476.35 GBP 1888.16 USD | — - | — — |
- {{ link.label }} {{link}}